Vanda Pharmaceuticals Inc.
VNDA
$5.24
-$0.10-1.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.02% | 8.16% | 8.72% | 11.12% | 11.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.02% | 8.16% | 8.72% | 11.12% | 11.78% |
| Cost of Revenue | 18.49% | 11.29% | 15.29% | -3.14% | -10.22% |
| Gross Profit | 5.28% | 7.97% | 8.32% | 12.09% | 13.43% |
| SG&A Expenses | 37.53% | 53.97% | 62.52% | 63.87% | 62.42% |
| Depreciation & Amortization | 6.74% | 3.35% | -3.66% | 8.23% | 37.29% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.92% | 38.11% | 53.39% | 45.91% | 41.86% |
| Operating Income | -84.18% | -121.34% | -271.79% | -223.13% | -210.47% |
| Income Before Tax | -108.48% | -169.13% | -504.89% | -492.44% | -610.61% |
| Income Tax Expenses | 640.74% | 889.70% | 2,134.99% | -1,251.97% | -1,646.52% |
| Earnings from Continuing Operations | -310.61% | -441.37% | -1,066.53% | -413.78% | -512.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -310.61% | -441.37% | -1,066.53% | -413.78% | -512.58% |
| EBIT | -84.18% | -121.34% | -271.79% | -223.13% | -210.47% |
| EBITDA | -90.64% | -135.40% | -339.80% | -274.92% | -249.92% |
| EPS Basic | -305.54% | -434.83% | -1,049.63% | -406.73% | -504.50% |
| Normalized Basic EPS | -91.83% | -139.25% | -364.52% | -318.02% | -336.42% |
| EPS Diluted | -303.94% | -429.52% | -1,021.34% | -390.21% | -474.97% |
| Normalized Diluted EPS | -91.83% | -139.25% | -364.52% | -318.02% | -336.42% |
| Average Basic Shares Outstanding | 1.62% | 1.43% | 1.36% | 1.36% | 1.32% |
| Average Diluted Shares Outstanding | 1.62% | 1.43% | 1.36% | 1.36% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |